Elite Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELTP research report →
Companywww.elitepharma.com
Elite Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products.
- CEO
- Nasrat Hakim
- IPO
- 2000
- Employees
- 64
- HQ
- Northvale, NJ, US
Price Chart
Valuation
- Market Cap
- $370.27M
- P/E
- 8.51
- P/S
- 2.64
- P/B
- 4.60
- EV/EBITDA
- 7.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 51.06%
- Op Margin
- 35.74%
- Net Margin
- 30.98%
- ROE
- 71.43%
- ROIC
- 34.42%
Growth & Income
- Revenue
- $84.04M · 48.42%
- Net Income
- $-4,314,659 · -121.46%
- EPS
- $-0.00 · -120.20%
- Op Income
- $19.60M
- FCF YoY
- 220.52%
Performance & Tape
- 52W High
- $0.82
- 52W Low
- $0.33
- 50D MA
- $0.37
- 200D MA
- $0.50
- Beta
- 0.38
- Avg Volume
- 583.20K
Get TickerSpark's AI analysis on ELTP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 9, 26 | Plassche Douglas | other | 2,500,000 |
| Jan 9, 26 | Plassche Douglas | other | 2,500,000 |
| Oct 2, 25 | Plassche Douglas | sell | 800,000 |
| Aug 25, 25 | ELITE PHARMACEUTICALS INC /NV/ | other | 2,500,000 |
| Aug 25, 25 | ELITE PHARMACEUTICALS INC /NV/ | other | 2,500,000 |
| Aug 22, 25 | ELITE PHARMACEUTICALS INC /NV/ | sell | 500,000 |
| Jul 10, 25 | Kirkov Kirko | buy | 16,366 |
| Jul 8, 25 | Plassche Douglas | sell | 200,000 |
| Jul 3, 25 | Plassche Douglas | other | 2,500,000 |
| Jul 3, 25 | Plassche Douglas | other | 2,500,000 |
Our ELTP Coverage
We haven't published any research on ELTP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELTP Report →